Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Amlodipine Besylate 10 Mg Tabs 1000 By Camber Pharma.

Image 0 of Amlodipine Besylate 10 Mg Tabs 1000 By Camber Pharma.Image 1 of Amlodipine Besylate 10 Mg Tabs 1000 By Camber Pharma.

Amlodipine Besylate 10 Mg Tabs 1000 By Camber Pharma.

Call for Price

Amlodipine Besylate 10 Mg Tabs 1000 By Camber Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD4095840/RXa310706/RXB10036705
Size : 1000
Selling UoM : EA
NDC: 31722-0239-10
UPC Barcode : 331722239103
Supplier: 0050001283 CAMBER PHARMACEUTICALS
Supplier Material : 023910
Generic Code : 016927 AMLODIPINE BESYLATE ORAL TABLET 10 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : G

Have a question?

  Call for Price

Product Description.:

IG, 239
tablet , white , round round
Flat-faced beveled-edgeDebossed

(amlodipine besylate) Tablets

DRUG DESCRIPTION

NORVASC? is the besylate salt of amlodipine, a long-acting calcium channel blocker.

Amlodipine besylate is a white crystalline powder with a molecular weight of 567.1. It is slightly soluble in water and sparingly soluble in ethanol. NORVASC (amlodipine besylate) tablets are formulated as white tablets equivalent to 2.5, 5 and 10 mg of amlodipine for oral administration. In addition to the active ingredient, amlodipine besylate, each tablet contains the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.

INDICATIONS
Hypertension

NORVASC is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Coronary Artery Disease (CAD)
Chronic Stable Angina

NORVASC is indicated for the symptomatic treatment of chronic stable angina. NORVASC may be used alone or in combination with other antianginal agents.
Vasospastic Angina (Prinzmetal's or Variant Angina)

NORVASC is indicated for the treatment of confirmed or suspected vasospastic angina. NORVASC may be used as monotherapy or in combination with other antianginal drugs.
Angiographically Documented CAD

In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, NORVASC is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure.
DOSAGE AND ADMINISTRATION
Adults

The usual initial antihypertensive oral dose of NORVASC is 5 mg once daily with a maximum dose of 10 mg once daily. Small, fragile, or elderly individuals, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding NORVASC to other antihypertensive therapy.

Dosage should be adjusted according to each patient's need. In general, titration should proceed over 7 to 14 days so that the physician can fully assess the patient's response to each dose level. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently.

The recommended dose for chronic stable or vasospastic angina is 5-10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect. See ADVERSE REACTIONS section for information related to dosage and side effects.

The recommended dose range for patients with coronary artery disease is 5-10 mg once daily. In clinical studies the majority of patients required 10 mg (see CLINICAL PHARMACOLOGY, Clinical studies).
Children

The effective antihypertensive oral dose in pediatric patients ages 6-17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients. See CLINICAL PHARMACOLOGY.
Co-administration with Other Antihypertensive and/or Antianginal Drugs

NORVASC has been safely administered with thiazides, ACE inhibitors, beta-blockers, long-acting nitrates, and/or sublingual nitroglycerin.

WARNINGS
Increased Angina and/or Myocardial Infarction

Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed documented increased frequency, duration and/or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been elucidated.

PRECAUTIONS

Since the vasodilation induced by NORVASC is gradual in onset, acute hypotension has rarely been reported after oral administration. Nonetheless, caution as with any other peripheral vasodilator, should be exercised when administering NORVASC, particularly in patients with severe aortic stenosis.